In August, OCRA hosted a listening session with the U.S. Food and Drug Administration (FDA) to better understand the impact of Covid-19 on clinical trial participation.
Watch the full FDA listening session in the video below.
Related Topics
The Overview: October 2025
KVIA-TV ABC-7 News El Paso recently featured OCRA-funded researcher Daniel Heller, PhD, and his team at Memorial Sloan Kettering Cancer Center, whose innovative work is bringing new hope for detecting ovarian cancer at its earliest stages through a simple blood test. Dr. Heller’s research lab is developing a liquid biopsy that uses nanosensors and artificial intelligence (AI) to measure multiple proteins … Continued
OCRA’s Advocate’s Corner: October 2025
Written by Chad Ramsey, Vice President, Policy, Ovarian Cancer Research Alliance Federal Update As of this writing, Congress has failed to come to an agreement on funding for the current fiscal year and the federal government is in a shutdown. We are closely monitoring the impact that the shutdown is having on the patient community and … Continued
OCRA Sponsors NCCN 2025 Guidelines for Cervical, Ovarian, and Uterine Cancer Patients
This article was updated in October 2025 to reflect NCCN’s release of the 2025 Guidelines for Uterine Cancer Patients. OCRA is a proud sponsor of the 2025 Patient Guidelines for Cervical, Ovarian, and Uterine Cancer. We believe ensuring access to clear, understandable information is critical. NCCN provides wonderful guides for anyone newly diagnosed to help … Continued